LLVK (TFA)
LLVK TFA is a selective IκB phosphorylation inhibitor. LLVK TFA reduces LPS-induced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) . LLVK TFA is promising for research of inflammatory bowel disease and rheumatoid arthritis[1].
Product Specifications
UNSPSC
12352209
Target
IKK; NF-κB
Related Pathways
NF-κB
Field of Research
Inflammation/Immunology
Purity
99.50
Smiles
O=C(O)C(F)(F)F.O=C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(O)=O)=O)=O)[C@H](CC(C)C)N
Molecular Formula
C25H46F3N5O7
Molecular Weight
585.66
References & Citations
[1]Liu W, et al. Alternation in sequence features and their influence on the anti-inflammatory activity of soy peptides during digestion and absorption in different enzymatic hydrolysis conditions. Food Chem. 2025 Apr 15;471:142824.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
